This Activity Requires You To Leave myCME.

You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.

You are about to open a webpage that is outside of this educational content.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
This CME Activity has expired and is no longer available for credit.
Treatment-Resistant, Hormone-Positive Breast Cancer: Next Steps & New Paradigms

Treatment-Resistant, Hormone-Positive Breast Cancer: Next Steps & New Paradigms



Time to Complete

1 hour


October 5, 2012


October 18, 2014

Updated Expiration Information

This CME-certified activity has been granted an extension for twelve months as the content was deemed relevant and current according to the standards set forth by the Society for Translational Oncology (STO) and Massachusetts General Hospital.

Release date: October 5, 2012
Review: October 18, 2013
Expiration date: October 18, 2014

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly sponsored by the Society for Translational Oncology and Massachusetts General Hospital.

Commercial Supporter

Supported through an educational grant from Genentech, Novartis, and Genomic Health

Program Description

Estrogen- and/or progesterone-positive breast cancer is highly responsive to endocrine therapy. However, such cancers nearly always develop endocrine resistance. The most appropriate management options for women with endocrine-resistant breast cancer are unclear, so it’s critical for clinicians to remain informed about the most clinically relevant outcomes of trials presented/published in the past 18 months, in order to most effectively manage treatment-resistant MBC.

Intended Audience

Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.

Educational Objectives

At the end of this online enduring material, participants should be able to:

  • Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
  • Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.


In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.

Michaela J. Higgins, Mb.Bch
Instructor in Medicine
Massachusetts General Hospital
Harvard Medical School

The speaker of this activity, Michaela J. Higgins, Mb.Bch, has indicated that neither she nor her spouse/partner have a relevant financial relationship to disclose.

Planning Staff Disclosure

The following planner of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose:
Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer


The Internet was selected as the medium for this activity to accommodate the learning preferences of a significant portion of the target audience.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Designation Statement

Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.


Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue